SOURCE: Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

April 15, 2015 08:30 ET

Critical Outcome Technologies Receives First U.S. Patent for Next Generation HIV Treatment

Second Generation HIV Integrase Inhibitor Compounds Discovered Using Proprietary Drug Discovery Platform Technology, CHEMSAS®

LONDON, ON--(Marketwired - April 15, 2015) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF) announced today that it has been granted a U.S. patent for the Company's novel HIV integrase inhibitor compounds.

"This important patent is our first for the treatment of HIV and validates our research as we look to identify the lead compound to advance through preclinical development," said Dr. Wayne Danter, President and CEO of COTI. "The highly novel compounds covered by this patent were discovered using our proprietary drug discovery platform technology, CHEMSAS®. Once selected, the final lead compound will be developed as a second generation HIV integrase inhibitor with a unique mode of action that differentiates it from current integrase inhibitor programs in the market or in development."

United States Patent No. 8987272 covers novel compounds useful in the treatment of HIV and methods of treating HIV using the compounds. The patent provides coverage for these compounds and methods until the year 2031. Equivalent patents are pending in Canada and Europe.

The Company is currently looking for a licensing or co-development partner for this preclinical program.

For additional information pertaining to this announcement, please visit our blog at www.criticaloutcomeblog.com/blog-posts.

About Critical Outcome Technologies Inc.

COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI's proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome

Notice to Readers
Information contained in this press release may contain certain statements, which constitute "forward- looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statements "…as we look to identify the lead compound to advance through preclinical development" and "once selected, the final lead compound will be developed as a second generation HIV integrase inhibitor with a unique mode of action that differentiates it from current integrase inhibitor programs in the market or in development" and "equivalent patents are pending in Canada and Europe" and "currently looking for a licensing or co-development partner for this preclinical program," are forward-looking statements. Forward‐looking statements, by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward‐looking statements. Management of COTI considers the assumptions on which these forward‐looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, visit www.criticaloutcome.com or:

Contact Information